Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 36.00 | |
2 mg | In stock | $ 51.00 | |
5 mg | In stock | $ 105.00 | |
10 mg | In stock | $ 148.00 | |
25 mg | In stock | $ 297.00 | |
50 mg | In stock | $ 558.00 | |
100 mg | In stock | $ 785.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 123.00 |
Description | Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion). |
Targets&IC50 | CCDC6-RET:0.4 nM, RET (WT):0.4 nM, RET (M918T):0.4 nM, RET (V804M):0.4 nM, RET (V804L):0.3 nM |
In vitro | Pralsetinib demonstrates more than 10-fold increased potency over approved MKIs against oncogenic RET variants and resistance mutants. Pralsetinib demonstrates potent activity (IC50: 0.4 nM) against common oncogenic RET alterations, including RET M918T, an activating mutation found in MTC, as well as the CCDC6-RET fusion observed in PTC and NSCLC. Pralsetinib suppresses RET pathway signaling in a panel of RET-driven cell lines: LC2/ad (CCDC6-RET, NSCLC), MZ-CRC-1 (RET M918T, MTC), and TT (RET C634W, MTC). |
In vivo | Pralsetinib potently inhibits the growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR-2. Pralsetinib shows dose-dependent activity against both KIF5B-RET Ba/F3 and KIF5B-RET V804L Ba/F3 allograft tumors with doses as low as 10 mg/kg twice daily. |
Synonyms | Blu667 |
Molecular Weight | 533.6 |
Formula | C27H32FN9O2 |
CAS No. | 2097132-94-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (178.04 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pralsetinib 2097132-94-8 Apoptosis Tyrosine Kinase/Adaptors c-RET Inhibitor BLU 667 BLU-667 Blu667 inhibit RET inhibitor